

# Rhopressa™ (netarsudil ophthalmic solution) 0.02%
# Rocket 2 Phase 3
# Interim 12-Month Safety Results

# Important Information

Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved by regulatory authorities.

The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to update this information in light of new information, future events or otherwise. We are not making any representation or warranty that the information in this presentation is accurate or complete.

Certain statements in this presentation are “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “will,” “should,” “would,” “could,” “believe,” “expects,” “anticipates,” “plans,” “intends,” “estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking statements. These statements are based on the Company’s current plans and expectations. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ materially from any forward-looking statements. These risks and uncertainties are described more fully in the quarterly and annual reports that we file with the SEC, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Such forward-looking statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as otherwise required by law.

# Rhopressa™ Achieves Positive Interim 12-month Safety Results

- FDA requires at least 100 patients on Rhopressa™ QD completing twelve-month period for NDA
- The first 118 patients on Rhopressa™ QD completed the twelve-month period
  - Adverse event profile in Month 12 similar to Month 3
  - Stable efficacy from Month 3 to Month 12
- On target to file NDA in Q3 2016

# Rocket 2: 8am IOP Efficacy

## Safety Population, Completed Patients (<27 mmHg)




- Difference in 8am mean IOP from Day 90 (Month 3) to Month 12:

  Rhopressa™ QD:

  - Full population: +0.1 mmHg
  - Subset analyses: -0.3 to +0.3 mmHg

  Timolol BID:

  - Full population: +0.5 mmHg
  - Subset analyses: +0.1 to +1.4 mmHg

# Safety/Tolerability Overview of Rhopressa™ QD (Interim 12-Month)

- There were no drug-related serious adverse events (SAEs)
- No new adverse events introduced over the twelve-month period
- The most common adverse event was conjunctival hyperemia
  - Increased conjunctival hyperemia measured by biomicroscopy at 8 am was ~30%* of which 76% was mild at month 12
  - Hyperemia was sporadic – 70% of patients with prior conjunctival hyperemia had no hyperemia at month 12
- Other ocular AEs
  - AEs occurring in ~5-23% of patients included: conjunctival hemorrhage, corneal deposits, blurry vision and reduced visual acuity

*Incidence of conjunctival hyperemia ~50% (baseline 20%)

# Rhopressa™ and Roclatan™ Key Milestones